Developing molecules simultaneously targeting two or all three PPAR isotypes is another promising approach for NAFLD treatment that allows targeting of the multifaceted roles of PPARs. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.